← Eichor
Study identifier: NCT07514637 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg/Kgevery 8 Hours for Three Consecutive Days After Surgery.

Condition: Patients Who Undergo Pancreaticoduodenectomy  ·  Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

PhasePhase 2
Planned participants35
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients. Main objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy. Secondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy. Exploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.

This description comes directly from the study's public registry record.

Talk to the study team

yudong QIU  ·  0086+13809021967  ·  yudongqiu510@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

NanJing drum tower hospitalNanjing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07514637